Concepedia

Author

Erkut Borazanci

HonorHealthORCID

Also Known As

Borazanci, Erkut H., Cynthia Lim, E Borazanci, E. Borazanci, Erkut Borazanci, Erkut H Borazanci, Erkut H. Borazanci, Erkut Hasan Borazanci

318

Publications

4.3K

Citations

27

H-Index

71

Concepts

All Affiliations

HonorHealthTranslational Genomics Research InstituteMayo Clinic in ArizonaMemorial Sloan Kettering Cancer CenterThe University of Texas Southwestern Medical Center
EB

About

Erkut Borazanci is an author at HonorHealth specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

18

1.5K

2

Health Sciences

4

4

71

3

Biochemistry

2

2

42

4

Engineering

1

1

11

5

Public Health

1

1

86

Erkut Borazanci

×

41

Publications

3.3K

Citations

23

H-Index

YearCitations

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Bruno Bockorny, Valerya Semenisty, Teresa Macarulla,

Nature Medicine

2020

501

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring

Yu Shi, Weina Gao, Nikki K. Lytle,

Nature

2019

413

Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions

Wei Lin, Pawan Noel, Erkut Borazanci,

Genome Medicine

2020

320

Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer

Thomas B. Karasic, Mark H. O’Hara, Arturo Loaiza‐Bonilla,

JAMA Oncology

2019

277

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau,

EClinicalMedicine

2021

250

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Davide Melisi, Do‐Youn Oh, Antoine Hollebecque,

Journal for ImmunoTherapy of Cancer

2021

178

An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study

Kota Nakamura, Zhongxu Zhu, Eunsung Jun,

Gastroenterology

2022

147

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

Kyriakos P. Papadopoulos, Erkut Borazanci, Alice T. Shaw,

Clinical Cancer Research

2020

103

Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma

Randall E. Brand, Erkut Borazanci, Virginia Speare,

Cancer

2018

86

A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors

David S. Hong, Drew Rasco, Michael H. Veeder,

Oncology

2019

81

Page 1